How ADPKD Guide decides what is proven, promising, weak, or unresolved
This public resource is built from the ADPKD repo using an evidence-first workflow. The goal is to keep useful nuance without turning the site into unreadable academic sludge.
Evidence rubric
# Evidence Rubric (ADPKD) ## Tier 1 — High-confidence human evidence Guidelines, systematic reviews/meta-analyses, RCTs, strong regulatory-grade evidence. ## Tier 2 — Moderate human evidence Observational cohorts, case-control studies, smaller interventional studies, repeated but limited findings. ## Tier 3 — Early clinical/translational signal Ongoing trials, pilot studies, subgroup signals, emerging biomarker-driven clinical signals. ## Tier 4 — Preclinical evidence Animal models, organoids, cell/mechanistic studies. ## Tier 5 — Theoretical/hypothesis-level Mechanistic hypotheses and inferred therapeutic strategies without direct validation. ## Required fields per claim - Claim - Evidence tier - Source (URL/citation) - Date - Study type - Disease relevance - Mechanism - Limitations - Confidence level - Replicated or contradicted
Source priority
# Source Priority ## Priority 1 (authoritative) - KDIGO - PubMed / PMC primary papers - ClinicalTrials.gov - FDA / EMA - NIH / NIDDK - Major peer-reviewed nephrology journals ## Priority 2 (strong supporting) - Europe PMC - PKD Foundation research pipeline pages - Crossref metadata - OpenAlex metadata and related-work graph - National Kidney Foundation - University/lab news pages only when linked to primary sources - Conference abstracts only when flagged as preliminary ## Priority 3 (signal only, must verify) - Company press releases - Media summaries - Expert commentary ## Exclusion / low trust by default - Anonymous forums and unsourced claims - Blogs without citations - social posts without primary-source linkage ## Verification rule No claim is promoted above Tier 3 unless validated by Priority 1 or strong Priority 2 sources. ## Source usage notes - Use PubMed, PMC, and Europe PMC for article discovery and verification. - Use ClinicalTrials.gov for trial status, phase, and recruitment tracking. - Use Crossref and OpenAlex for DOI enrichment, citation cleanup, and related-paper discovery. - Use PKD Foundation pages as public pipeline cross-checks, not as replacements for primary evidence.